Form 4: Ventyx Director Reports Share Disposition Post-Eli Lilly Merger

Ventyx Biosciences Director Sheila Gujrathi reports the disposition of common stock and cancellation of stock options following the company's acquisition by Eli Lilly and Company.

Summary

• Sheila Gujrathi, a Director of Ventyx Biosciences, Inc., reported changes in her beneficial ownership due to the merger with Eli Lilly and Company.
• Ventyx Biosciences, Inc. became a wholly-owned subsidiary of Eli Lilly and Company through the merger, effective March 4, 2026.
• 130,000 shares of Ventyx common stock were automatically converted into cash at $14.00 per share.
• Stock options with an exercise price less than or equal to $14.00 per share (totaling 815,369 underlying shares) were cancelled and converted into a cash payment based on the difference between the $14.00 per share price and the option's exercise price.
• Stock options with an exercise price greater than $14.00 per share (totaling 315,703 underlying shares) were cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Ventyx shareholders who received cash for their shares and in-the-money options, reflecting a successful acquisition. The cancellation of out-of-the-money options is a standard outcome in such scenarios.

Positives

• The reporting person received cash for 130,000 shares of common stock at $14.00 per share.
• In-the-money stock options were converted into cash payments, providing liquidity for those holdings.

Negatives

• Out-of-the-money stock options (with exercise prices greater than $14.00 per share) were cancelled for no consideration, resulting in a loss of potential value for those options.

Risks

• Stock options with an exercise price greater than the $14.00 Per Share Price were cancelled for no consideration, representing a loss of value for the holder.

Future Outlook

The filing indicates that Ventyx Biosciences, Inc. has become a wholly-owned subsidiary of Eli Lilly and Company, implying its future operations and strategic direction will be integrated under the parent company's umbrella. No independent forward-looking statements for Ventyx are provided.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly and Company is consistent with the broader pharmaceutical industry trend of larger players acquiring smaller biotech firms to bolster their pipelines and intellectual property. Such mergers often provide significant premiums to target company shareholders, reflecting the strategic value of their assets.

Comparison to Industry Standards

• StockSavvy.ai observes that the acquisition price of $14.00 per share for Ventyx Biosciences aligns with typical premiums seen in biotech M&A, where valuations often reflect pipeline potential and market positioning.
• Similar acquisitions in the immunology or inflammatory disease space, such as Pfizer's acquisition of Arena Pharmaceuticals for $6.7 billion (approximately $100 per share) or Bristol Myers Squibb's acquisition of MyoKardia for $13.1 billion (approximately $225 per share), demonstrate the strategic value placed on specialized drug developers.
• While the specific per-share price varies based on company size, stage of development, and market conditions, the structure of converting shares to cash and handling options is standard practice in such transactions.

Stakeholder Impact

• Shareholders: Received $14.00 per share in cash for their common stock, providing liquidity and a premium (if applicable) as a result of the merger.

Next Steps

• Ventyx Biosciences, Inc. will operate as a wholly-owned subsidiary of Eli Lilly and Company.
• The common stock of Ventyx Biosciences, Inc. will no longer be publicly traded.

Key Dates

Keywords

Ventyx Biosciences, VTYX, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Sheila Gujrathi